Recursion Pharmaceuticals Inc. RXRX shares are trending on Friday. Shares of the Utah-based clinical-stage biotechnology ...

Recursion Pharma launches a $200M equity offering and reports a Sanofi milestone but is rated a Hold on limited near-term ...

I was thinking about a program to solve Sudoku.You fill a 9x9 grid with numbers from 1 to 9. The same number must not be ...

Recursion Pharmaceuticals Inc. announced Thursday that Sanofi has selected the first development candidate under their research collaboration, triggering a $10 million milestone p ...

There has been another major milestone in the field of AI-driven drug discovery (AI drug discovery).I would like to organize ...

On Thursday, Recursion Pharmaceuticals ( RXRX) priced an offering of 61.54 million Class A shares at $3.25 each, expecting to raise approximately $200 million before expenses. The offering is expected ...

Recursion (RXRX) stock dips after $200M equity offering despite Sanofi (SNY) choosing its first AI drug candidate under a ...

Prices displayed are informational. Learn more Recursion Pharmaceuticals (RXRX) said Thursday it priced an offering of 61.5 million shares at $3.25 each to raise gross proceeds of about $200 million.

Leading Healthcare Investors, including Janus Henderson Investors, Invus, Longaeva Partners, ARK Invest, Driehaus Capital ...

Recursion Pharmaceuticals announced a $10 million milestone payment from Sanofi for a new drug candidate targeting ...

Recursion Pharmaceuticals (NASDAQ: RXRX) priced an underwritten public offering of 61,540,000 shares of its Class A common stock at $3.25 per share, according to a press release issued Oct. 15, ...